1. Abood, M. E., & Martin, B. R. (1992). Neurobiology of marijuana abuse. Trends in Pharmacological Sciences, 13, 201–206.
2. Aceto, M. D., Scates, S. M., Lowe, J. A., & Martin, B. R. (1995). Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. European Journal of Pharmacology, 282, R 1 — R2.
3. Adler, M. W., & Geller, E. B. (1986). Ocular effects of cannabinoids. In R. Mechoulam (Ed.), Cannabinoids as therapeutic agents (pp. 51–70 ). Boca Raton, FL: CRC.
4. Agurell, S., Hal!din, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986). Pharmacokinetics and metabolism of delta I-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacological Reviews, 38, 21–43.
5. Bhargava, H. N. (1978). Potential therapeutic applications of naturally occurring and synthetic cannabinoids. General Pharmacology, 9, 195–213.